A Clinical Trial to Study the Efficacy and Safety of Insulin Aspart Three Times Per Day Compared to Glibenclamide Once or Twice Daily in Type 2 Diabetes by Comparison of Ability to Control Blood Glucose.
Phase of Trial: Phase III
Latest Information Update: 08 Mar 2016
At a glance
- Drugs Glibenclamide; Insulin aspart
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 31 Aug 2018 Biomarkers information updated
- 23 Sep 2011 Planned end date (Apr 2006) added as reported by ClinicalTrials.gov.
- 21 Aug 2006 New trial record.